Green for Green
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sashasees, I think you are right on target. Some of us still have faith in this company. Some of the others here, are probably candidates for the Wizard of Oz remake
I'm holding for the long term. The major research institutions involved, are the key ... for me. Sell if you must. GLTA who are holding.
According to one of the other boards, this has a 1 yr. target of $9.00 They must be up to something serious to expect that.
An interesting article from about 5 years ago. Note the November 16, 2011 date, for reference:
http://www.cureparalysisnow.org/forum/viewtopic.php?f=19&t=237
SCOTCH PLAINS, N.J.--(BUSINESS WIRE)--Stem Cell Innovations, Inc. (OTCBB: SCLL) announced today that it had raised $1 million through the issuance to an existing investor of a secured convertible note and warrants to purchase 10,000,000 shares of the Company’s common stock. The convertible note, due November 16, 2007, is in the principal amount of $1 million, bears interest at the rate of 10% per annum, is secured by all the assets of the Company and its subsidiaries, and is convertible into 10,000,000 shares of the Company’s common stock. The warrants are exercisable until November 16, 2011 at a price of $.12 per share. The note and the warrants are subject to full ratchet antidilution provisions. The investor has committed to invest an additional $1 million on the same terms, within 60 days of the closing date, subject to the continued satisfaction by the Company of the conditions required to be satisfied with respect to the current offering. The Company paid a fee equal to $25,000 and 250,000 shares of common stock in connection with the transaction and will pay the same fee upon the completion of the additional $1 million investment.
About Stem Cell Innovations
Stem Cell Innovations is a cell biology company with facilities in Scotch Plains, NJ, Houston, TX and Leiden, the Netherlands. Our proprietary, human pluripotent stem cells, known as PluriCells™, have the potential to aid in drug discovery, toxicology, and cell therapy. We are in the process of making our patented pluripotent cell lines, which are eligible for federal funding in the United States, widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.
We are positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands our currently marketed C3A human liver cell-based toxicology offerings.
Additional information is available at http://www.stemcellinnovations.com.
Almost 15 million traded today. Take note ...
Yesterday's news about GERN and their second patient being treated, could help scll:
http://www.reuters.com/article/2011/05/10/stemcells-spine-idUSN1010116320110510?feedType=RSS&feedName=companyNews&rpc=43
How do you explain the ST shares showing N/A and no value?
2.8 million+ shares at .0080 for over $20,000?
I like it when the otcmarkets page on a position, shows names and addresses under the Service Providers:
http://www.otcmarkets.com/stock/EDWY/company-info
Service Providers
Auditor/Accountant
CCR LLP
125 High Street, 21st Floor
Boston, MA, 02110
United States
Legal Counsel
Arne M. Ray & Associates
5100 Westheimer Rd
Houston, TX, 77056
United States
Gersten Savage As of 11/1/2010
600 Lexington Avenue
New York, NY, 10022
United States
Investor Relations Firm
Heritage Corporate Services, Inc.
3040 Canterbury Dr.
Boca Raton, FL, 33434
United States
By Comparison, a certain medical electronics records stock has a similar share structure, around 3 Billion. If you watched it a few days ago, it went above .015 and is sitting in the .0060s range now. EDWY could run just as heavy ....
From:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48113
eDOORWAYS INTERNATIONAL CORPORATION
Disclosure Statement - First Quarter, 2011
Part B Share Structure
Item IV The exact title and class of Securities outstanding: Series A convertible preferred stock, $0.001 par value per share; 7,000,000 shares authorized, none issued Series B convertible preferred stock, $0.001 par value per share; 1,100,000 shares authorized, none issued Series C convertible preferred stock, $0.001 par value per share; 1,000,000 shares authorized, 1,000,000 issued and outstanding Series D preferred stock, $0.001 par value per share; 1,000 shares authorized, issued and outstanding Series F preferred stock, $0.001 par value per share; 50,000,000 shares authorized, issued and outstanding Series G preferred stock, $0.001 par value per share; 60,000,000 shares authorized; 47,695,426 shares authorized, issued and outstanding. Series H preferred stock, $0.001 par value per share; 10,000,000 shares authorized, 5,952,381 shares issued Common stock, $0.001 par value per share; 4.7 billion shares authorized; 3,403,547,271 outstanding CUSIP number: 281373100 The trading Symbol is EDWY
Item V Par or stated value and description of the security:
A. Par value or stated value
Series A, B, C, D, F, G & H of preferred stock are all at $0.001 par value
All Common stock has a par value of $0.001
B. Common or Preferred Stock
1. Common stock has voting rights and to date no dividends have been issued.
2. The Board of Directors is vested with the authority to fix the voting powers and other designations of each class of stock. The Board has not made any such designations of the Series A, B, F, G and H Convertible Preferred Stock. On December 4, 2007, the Board of Directors designated that the Series C Convertible Preferred Stock would:
· Carry voting rights five times the number of common stock votes;
· Carry no dividends;
· Carry liquidating preference eight times the sum available for distribution
to common shareholders;
· Can automatically convert after one year after issuance to 20 common shares;
and
· Not be subject to reverse stock splits and other changes to the common stock of
eDoorways International Corporation.
Series D preferred stock carries the same dividend rights as common stock and allow the holder of the outstanding shares voting rights equal to 51% of all voting stock, preferred and common.
3.There are no other material rights of common or preferred stock.
4. None
Item VI The Number of shares or total amount of securities outstanding for each class of securities authorized.
Class A Preferred Stock as of April 11, 2011- 7,000,000 shares authorized none issued
Class B Preferred Stock as of April 11, 2011- 1,100,000 shares authorized none issued
Class C Preferred Stock as of April 11, 2011- 1,000,000 share authorized and 1,000,000
outstanding. There are none of these shared being traded currently. There are two
beneficial owners of these shares. There are only two owners of these shares.
Class D Preferred Stock as of April 11, 2011 there are 1,000 shares authorized and 1,000
issued and outstanding to one beneficial owner.
Class E None Created
Class F Preferred Stock as of April 11, 2011 – 50,000,000 shares authorized and 50,000,000
outstanding. There is one beneficial owner of these shares.
Class G Preferred Stock as of April 11, 2011 – 60,000,000 shares authorized; and
47,695,426 issued and outstanding to two beneficial owners.
Class H Preferred Stock as of April 11, 2011 – 10,000,000 shares authorized and 5,952,381
issued and outstanding to one beneficial owner.
Preferred Stock as of April 11, 2011 there are 300 million shares authorized.
Common Stock as of April 11, 2011 there are 4.7 billion shares authorized and 3,403,547,271
issued and outstanding.
The Public float of Common stock as of April 11, 2011 is 2,998,782,464
The total number of beneficial shareholders as of April 11, 2011 is 9
The total number of shareholders of record as of April 11, 2011 is 166
How many received the great news about mdfi from one of the penny stock newsletters? I did, but kept out of the carnage today. Make sure to thank those newsletters for your big losses if you had them today. Will tomorrow offer any redemption?
Ian Lyons (Chief Scientific Officer) used to be affiliated with this company. Does anyone know if he still is?
Did you read the article from yesterday. Just found it posted elsewhere,
http://www.hotstocked.com/article/4481/elite-pharmaceuticals-inc-otc-eltp-surges-to-a.html
Elite Pharmaceuticals, Inc. (OTC:ELTP) Surges to a New Yearly High, But the Future Is Uncertain
By Violeta Slavtchevska
Date: Apr 11, 2011
Last week the share price of Elite Pharmaceuticals, Inc. (OTC:ELTP, ELTP message board) surged to a new 52-week high as the company finally closed the third part of its strategic alliance agreement, with a delay of three months. Being in default on its debt, however, ELTP survival seems now to depend more on its ability to come to an agreement with its lender than on the development of its products.
ELTP closed the last trading session at $0.091 and only with a 1.11% increase in the share price. The real surge happened the day before that and the stock reached a new yearly high at $0.11 and a record for the past year trading volume of 15 million shares.
It looks like the news that triggered the action was that Elite Pharmaceuticals has completed the Third Closing of its Strategic Alliance Agreement with Epic Pharma, LLC and its wholly-owned subsidiary Epic Investments, LLC.
Under that agreement, ELTP partner has invested in the company and the two companies have agreed to work together on the development of at least eight generic drug products. The third part of the agreement was supposed to happen by December 31, 2010 and along with the delay, now the terms have also been amended. In addition to the 1,000 shares of Series E Preferred Stock, convertible into 32,784,623 ELTP shares of common stock, the company delivered to its partner and investor also a warrant. Epic can thus purchase up to 40 million ELTP common shares at a price of $0.0625 per share, while the cash received by ELTP remains $1 million.
Although Elite should now use the funds to keep working on its products, but the latest 10-Q says that the company is unlikely to get profitable over the next two years and that it has a huge liquidity problem that even puts its further existence under question. ELTP has an outstanding bond, for which it could not pay the principal amount that was due in September last year. Thus, a notice of default has been received and the total amount of $3.4 million owed to the holders of the bond has been recorded as current liability.
Together with its other current liabilities, the company had at the end of last year working capital deficit of $2.6 million. The bonds are collateralized by ELTP facilities and equipment, and the management believes that the resolution of that issue will have a significant impact on the company's ability to operate in the future.
0.0881 -0.0245 -21.76% 6,894,948 shares traded bid 0.0881 ask 0.089 ... 10 minutes to go.
Various reasons, such as interpretations of the action, to downright FEAR.
Look at the "wall" on this chart, from yesterday to today:
http://www.google.com/finance?q=bmod
How many lemmings went over that?
This one is running very similar to vkng in Fall of 2009.
That's what I am thinking. Just too many birds flying from tree to tree on other positions today:
http://investorshub.advfn.com/boards/tcloud2.aspx
For those with ST, enter BMOD in the upper right-hand corner of your home page ... detailed quote. Then, look at the lower right-hand portion of the page that takes you too. Did you notice how BMOD compares to its peers? And, make sure to read the entire 10-K, which is 67 pages long ... that is imperative for any long-term investor, in my opinion.
Some of the other online brokerages are like that too, on some stocks that they consider to be too risky, or whatever. The first time I came across a "red screen" and had to call the order in, I let them talk me out of buying it. The stock was ROIAK, and was at 4 cents. It went up to the $1.50 range within a year.
Share Structure, Funding & up-to-date website:
http://www.biomoda.com/
Today's PR was excellent ...
"The University of Texas Health Science Center at San Antonio ranks in the top 3% of all institutions worldwide receiving federal funding."
From today's PR
Like lemmings jumping off a cliff Look at the chart:
http://ih.advfn.com/p.php?pid=webchart&symbol=BMOD&period=0&size=19&volume=1
Weak hands shaken from the tree?
Lots of Patents:
The Company amortizes patent expense over the useful life of the patent, which is twenty years from the date of application, using a straightline method. This represents a change from the estimated useful life applied in previous years, which was seventeen years from the date of issuance.
Biomoda, Inc. owns U.S. Patent 6,838,248, titled “Compositions and Methods for Detecting Pre-Cancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine” which was issued on January 4, 2005;
U.S. Patent 7,384,764, titled “Method for Prognosing Response to Cancer Therapy with 5,10,15,20 - Tetrakis (Carboxyphenyl) Porphine” which was issued June 10, 2008;
U.S. Patent 7,670,799 titled “Method for Making 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) Solution and Composition
Comprising TCPP” which was issued on March 2, 2010;
Allowed U.S Patent Application 12/715,627 titled “Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis
(Carboxyphenyl) Porphine” filed March 2, 2010; and
Foreign equivalents of these inventions were granted in Canada, Japan, Mexico, and Australia and is pending in Europe.
Biomoda owns pending U.S. Patent Application 12/839,283 titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP)” which provides a quantitative method for reading tissue samples for signs of malignant cells based on flow cytometry and dark-field microscopy which was filed on July 19, 2010; and
Patent Cooperation Treaty (“PCT”) Application PCT/US10/42482 titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP)” filed July 19, 2010.
Biomoda owns U.S. registrations for the marks CyPath® and CyDx® and a U.S. registration is pending for the mark “Biomoda”. The
Company has also received registrations for the marks Biomoda® , CyPath® and CyDx® in the European Union.
I am guessing we will see more swings tomorrow. It reminds me of ctic when it was in the 5 to 20 cent range ... then it took off to the dollars.
Security Notes
Capital change= Shares increased by 66.113 for 1. Ex-date= 10-18-04
Capital Change=shs decreased by 1 for 400 split Pay date=10/24/2007.
Capital Change=shs decreased by 1 for 10,000 split. Pay date=12/01/2008.
http://www.otcmarkets.com/stock/GRBT/company-info
http://www.otcmarkets.com/stock/hhgi/company-info
Security Notes
Capital Change=shs decreased by 1 for 100 split Pay date=09/12/2008.
Capital Change=shs decreased by 1 for 200 split Pay date=08/14/2009.
Capital Change=shs increased by 10 for 1 split. Ex-date=02/11/2010. Rec date=01/29/2010. Pay date=02/10/2010.
Company Notes
Formerly=Castle Technologies, Inc. until 8-2009
Formerly=ImagiTrend, Inc. until 4-2008
Formerly=GeckoSystems, Inc. until 8-07
Formerly=International Shoe Manufacturing Corp. until 11-06
Share Structure
Market Value1 $426,668 a/o Mar 17, 2011
Shares Outstanding 1,422,226,480 a/o Mar 15, 2011
Float 211,807 a/o Mar 15, 2011
Authorized Shares 5,000,000,000 a/o Dec 31, 2010
Par Value 0.0001
Is the share structure still?
A/S: 20 Billion
O/S: 1.9 Million
University Partners:
http://suti.com/Portfolio/UniversityPartners.html
"The Select University Technologies Inc. robust portfolio of relationships with prestigious American universities is unique and strategic. This wellspring of pure science is a current and continuing source of new technology. SUTI employs a refined system to review, evaluate, challenge and ultimately select patented intellectual property that holds strong promise for successful commercialization. For more than 50 years, American universities have been regarded as the cornerstone of technology development in the United States. Remarkably, this spectacular fountainhead of technology remains largely unexploited."
Boston University, Boston MA
Clemson University Clemson SC
Florida State University, Tallahassee FL
Rutgers State University of New Jersey,
New Brunswick NJ
University of Arkansas, Fayetteville AR
University of Dayton Research Institute, Dayton OH
University of Massachusetts at Amherst, Amherst MA
University of New Mexico, Albuquerque NM
University of Rochester, Rochester NY
University of Southern California, Los Angeles CA
Virginia Tech, Blacksburg VA
From their brochure:
http://suti.com/pdfs/SUTI-storyA-16pg-03.05.07.pdf
"Selection Criteria and Development Process
SUTI considers projects from all scientific fields, with
strong emphasis in communications, electronics,
nano-materials and tools, software and information
systems, advanced construction materials and
techniques, environmental sensing, and energy.
Prospective development companies must meet the
minimum criteria of projected:
• exit event of $200 million or greater
• cumulative revenues of $150 million over the first
five years
• product in the market with first sale in 18 months
• positive cash flow within 36 months of initial
investment"
The big names are there. There is no telling how far this will go.
Did you notice the company names on the Suti homepage?
http://suti.com/Portfolio/Companies.html
What about the listing of University partners?
http://suti.com/Portfolio/UniversityPartners.html
Intellistick: Popular Mechanics Editors Choice
http://www.intellistick.com/
Check the Historical Prices:
http://ih.advfn.com/p.php?pid=historical&symbol=GARB
50 BILLION A/S appears disturbing. O/S & Float looks OK.
How many employees?
http://www.otcmarkets.com/stock/EVPH/company-info
Profile Data
SIC - Industry Classification 4813 - Telephone communication, except radio
Business Status Development Stage Company a/o Nov 16, 2010
Incorporated In: TX, USA
Year of Inc. 2003
Employees 2 a/o Nov 16, 2010
Dow down about 200 points ... could that be it?
Can anyone elaborate on the 1 Feb 2011 news about MWIS?
http://www.reuters.com/finance/stocks/overview?symbol=MWIS.OB
What was the outcome?